Full Press Release Details
Ultragenyx Reports Second Quarter 2025 Financial Results and Corporate Update.
RARE
Ultragenyx Reports Second Quarter 2025 Financial Results and Corporate Update
Key Takeaway: Ultragenyx Reports Second Quarter 2025 Financial Results and Corporate Update
Price reaction · baseline $28.46 (2025-08-04 close) · hit after-hours · clean, no other RARE news in the window
day 0 close · peak
+1.6%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+43%
120-day peak, hindsight
Typical move
2.9%
average across 6 past catalysts
Cash runway
~13 mo
Low dilution risk
Lead asset
BPS804
Phase 2 · Hypophosphatasia